EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische StudieOpen Access

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial

Martin Hutchings iD, Anna Sureda iD, Francesc Bosch iD, Thomas Stauffer Larsen iD, Paolo Corradini iD, Abraham Avigdor, María José Terol iD, Antonio Rueda Dominguez iD, Antonio Pinto, Alan Skarbnik, Raul Cordoba iD, Judit Meszaros Jørgensen und 8 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-00992 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Martin Hutchings und 19 weiteren Autor:innen. Beteiligte Einrichtung: Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.gov identifier: NCT03533283 ) investigating efficacy and safety of glofitamab plus polatuzumab vedotin (Glofit-Pola) in patients with R/R LBCL, including HGBCL and those who received previous chimeric antigen receptor (CAR) T-cell therapy. METHODS Patients received 1,000 mg obinutuzumab on Cycle (C)1 Day (D)1 (once daily). Polatuzumab vedotin (1.8 mg/kg) was given on C1D2 and D1 of C2–6 (21-day cycles; once daily). Glofitamab was given as step-up doses in C1 (D8, 2.5 mg; D15, 10 mg) followed by 30 mg on D1 of C2–12 (21-day cycles; once daily). Polatuzumab vedotin was given for six fixed-duration cycles, and glofitamab for 12. RESULTS As of September 2, 2024, 129 patients with LBCL (HGBCL; n = 44, 34.1%), received ≥1 dose of study treatment. The median age was 67 years (range, 23-84), and 63.6% were male. Patients had received a median of 2 (range, 1-7) previous lines of treatment (previous CAR T-cell therapy, n = 28, 21.7%). The independent review committee–assessed overall response rate was 78.3% (complete response rate, 59.7%). The median progression-free survival and overall survival (OS) were 12.3 and 33.8 months, respectively (median OS follow-up time, 32.7 months). The most common adverse event (AE) was cytokine release syndrome (43.4%; grade 1-2: 41.9%; one grade 5 event). Grade 3-4 AEs occurred in 58.9% of patients; 9.3% had grade 5 AEs, and 14.7% discontinued treatment because of AEs. CONCLUSION Glofit-Pola demonstrated high efficacy and durable responses, with manageable safety, in heavily pretreated patients with R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overImmunoconjugatesAntibodies, Monoclonal, HumanizedAntibodies, BispecificNeoplasm GradingAntibodies, Monoclonal

Substanzen

polatuzumab vedotinImmunoconjugatesAntibodies, Monoclonal, HumanizedAntibodies, BispecificAntibodies, Monoclonal

Autor:innen und Institutionen

  • Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
  • Clinical Hematology División, Institut Català d'Oncologia-L'Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
  • University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Odense University Hospital, Odense, Denmark.
  • University of Milano and Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Martin Hutchings, Anna Sureda, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, María José Terol, Antonio Rueda Dominguez, Raul Cordoba, Pier Luigi Zinzani, Alessia Bottos, Giuseppe Gritti

Zitieren

APA

Hutchings, M., Sureda, A., Bosch, F., Larsen, T. S., Corradini, P., Avigdor, A., Terol, M. J., Dominguez, A. R., Pinto, A., Skarbnik, A., Cordoba, R., Jørgensen, J. M., Zinzani, P. L., Leung, W., Bottos, A., Li, D., Relf, J., Tandon, M., Sellam, G., & Gritti, G. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00992

Vancouver

Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, et al. Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00992

BibTeX
@article{Hutchings2025,
  author = {Hutchings, Martin and Sureda, Anna and Bosch, Francesc and Larsen, Thomas Stauffer and Corradini, Paolo and Avigdor, Abraham and Terol, María José and Dominguez, Antonio Rueda and Pinto, Antonio and Skarbnik, Alan and Cordoba, Raul and Jørgensen, Judit Meszaros and Zinzani, Pier Luigi and Leung, Wilfred and Bottos, Alessia and Li, Donghang and Relf, James and Tandon, Maneesh and Sellam, Gila and Gritti, Giuseppe},
  title = {Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-00992}
}
Kostenlos starten →